Most Recent
A judge has denied law firm Piper Alderman's request to replace an uncooperative expert witness in a class action against KPMG over a failed takeover offer, three weeks before the matter goes to trial.
Property listing rivals REA Group and Domain have settled a trade mark lawsuit over an agreement between Domain and the owner of US website realestate.com to redirect Australian traffic to Domain's website.
Generic drug maker Sandoz must pay $26.34 million to Danish pharmacuetical giant Lundbeck and a subsidiary for infringing the Australian patent behind the blockbuster antidepressant Lexapro, a judge has found.
A $5.8 million bill for four years' work by the liquidators of SK Foods unit Cedenco has been criticised by a judge as "outside the band of reasonable remuneration" and will have to be recalculated.
A judge has put a proposal for a common fund order in a class action against sandalwood producer Quintis on hold as the court awaits judgment in an historic challenge to the power of courts to make common fund orders.
Poppy processor TPI Enterprises has agreed to stop selling seed from high codeine poppy plants while it defends a lawsuit by rival Tasmanian Alkaloids alleging TPI infringed two of its innovation patents for high codeine-concentrated poppy.
AFT Pharmaceuticals has launched a partial challenge to a court ruling that its Maxigesic ads made a number of misleading claims, including that the drug provides stronger and more effective relief than Reckitt Benckiser's Nuromol.
Pharmaceutical giant Wyeth has shot down arguments by rival Merck Sharp & Dohme that its Prevnar 13 vaccine lacked inventiveness, saying during the closing submissions of a high-stakes patent trial that up until it developed the top-selling shot scientists thought there was a "ceiling" of 11 types of pneumococcal bacteria that could be included in a single vaccine.
Maurice Blackburn has dropped its investigation of a possible class action on behalf of owners of units in Sydney's faulty Opal Tower, but Corrs Chambers Westgarth is still pursuing a potential case.
Claims by Wyeth that its patented Prevnar 13 pneumococcal vaccine was inventive because other pharmaceutical giants had failed in developing similar vaccines are based on "hearsay and speculation," Merck Sharp & Dohme told the court during closing submissions in the high-stakes trial over the world's best-selling vaccine.